International Stem Cell (ISCO) Non-Current Assets (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Non-Current Assets of $1.4 million for Q4 2025, down 12.71% year-over-year from $1.6 million in Q4 2024, and down 9.04% quarter-over-quarter from $1.5 million in Q3 2025.
International Stem Cell (ISCO) Non-Current Assets (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Non-Current Assets for 16 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets fell 12.71% year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $6.4 million (down 5.91% YoY), while the FY2025 annual figure was $1.4 million, down 12.71% from the prior year.
- Non-Current Assets fell to $1.4 million in Q4 2025 per ISCO's latest filing, from $1.5 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $3.0 million in Q1 2021 and bottomed at $1.4 million in Q4 2025.
- Historically, Non-Current Assets has averaged $2.1 million across 5 years, with a median of $2.0 million in 2023.
- Annual changes were most pronounced in 2021 — Non-Current Assets declined 23.88% — and 2025, when it climbed 0.56%.
- International Stem Cell's Non-Current Assets stood at $2.6 million in 2021, then declined by 16.85% to $2.2 million in 2022, then retreated by 13.95% to $1.9 million in 2023, then dropped by 13.7% to $1.6 million in 2024, then declined by 12.71% to $1.4 million in 2025.
- Business Quant data shows ISCO's Non-Current Assets at $1.4 million in Q4 2025, $1.5 million in Q3 2025, and $1.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 1.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.14 Mn |
| Dec 31, 2025 | 1.41 Mn |
| Sep 30, 2025 | 1.55 Mn |
| Jun 30, 2025 | 1.71 Mn |
| Mar 31, 2025 | 1.79 Mn |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | 1.69 Mn |
| Jun 30, 2024 | 1.78 Mn |
| Mar 31, 2024 | 1.78 Mn |
| Dec 31, 2023 | 1.87 Mn |
| Sep 30, 2023 | 1.98 Mn |
| Jun 30, 2023 | 2.10 Mn |
| Mar 31, 2023 | 2.11 Mn |
| Dec 31, 2022 | 2.17 Mn |
| Sep 30, 2022 | 2.34 Mn |
| Jun 30, 2022 | 2.42 Mn |
| Mar 31, 2022 | 2.54 Mn |
| Dec 31, 2021 | 2.61 Mn |
| Sep 30, 2021 | 2.45 Mn |
| Jun 30, 2021 | 2.83 Mn |